Bispecific κλ bodies targeting CD47 and membrane proximal epitopes on MSLN afford enhanced efficacy in vitro and in vivo.
In a study recently published in mAbs, we demonstrate that when designing dual targeting bispecific antibodies, the targeted region on a tumor-associated antigen needs to be carefully considered to ensure maximal effector function.
In the context of MSLN-positive solid tumors, we showed that kappa lambda bodies targeting a membrane-proximal epitope coupled to a CD47-blocking arm afforded an improved ADCC and ADCP profile, translating into increased in vivo efficacy.
